Experts Agree on 35 Outcomes to Measure Whether T2D Treatments Actually Modify Disease
A landmark Delphi consensus defines 35 core outcomes across 11 domains to standardize disease-modification trials in type 2 diabetes.
Summary
Type 2 diabetes has long been managed by controlling blood sugar and cardiovascular risk, but whether treatments can actually alter the disease's underlying trajectory has been harder to measure — partly because no agreed-upon outcome framework existed. An international panel of clinicians, researchers, and patients used a structured Delphi process to build that framework. Across two rounds involving over 230 participants, the group reached consensus on 35 outcomes spanning 11 domains. This core outcome set is designed to make future disease-modification trials more consistent and comparable, and to push the field beyond glycemic control toward genuinely altering how type 2 diabetes progresses — a shift with major implications for long-term healthspan and complication prevention.
Detailed Summary
Type 2 diabetes affects hundreds of millions of people worldwide and is a major driver of accelerated aging, cardiovascular disease, kidney failure, neuropathy, and premature death. Despite growing evidence that disease progression can be modified — not merely managed — clinical trials have lacked a shared vocabulary for what "disease modification" actually means. Without standardized outcomes, comparing interventions or designing trials that test whether a drug, lifestyle change, or surgical procedure truly alters disease trajectory has been nearly impossible.
To address this gap, an international multidisciplinary team led by researchers at the University of Leicester and Harvard Medical School conducted a modified Delphi consensus process following COMET (Core Outcome Measures in Effectiveness Trials) guidance. Candidate outcomes were first identified from the scientific literature and then refined by a steering group that included clinicians, diabetes researchers, and people living with type 2 diabetes — ensuring that patient-relevant outcomes were captured alongside clinical endpoints.
The process involved two formal Delphi rounds. Round one engaged 233 participants; round two retained 79. Through iterative voting and feedback, the panel reached agreement on 35 core outcomes organized across 11 domains. The framework spans biological, functional, and patient-reported dimensions, reflecting the heterogeneous nature of type 2 diabetes and its downstream complications.
For clinicians and longevity-focused practitioners, this consensus is practically significant. It sets the stage for trials that can finally answer whether interventions — from GLP-1 receptor agonists to intensive lifestyle programs — genuinely modify type 2 diabetes rather than simply lowering HbA1c. Given that metabolic dysfunction is one of the most powerful drivers of biological aging, a validated disease-modification framework could accelerate the identification of truly disease-altering strategies.
Caveats include the abstract-only availability of the full methodology and outcome list, broad industry conflicts of interest among panel members, and the inherent limitations of consensus methods in capturing emerging biomarkers.
Key Findings
- 35 core outcomes across 11 domains were agreed upon to define disease modification in type 2 diabetes.
- The Delphi process included clinicians, researchers, and patients — ensuring patient-centered outcomes were represented.
- The framework shifts focus beyond glycemic control toward genuinely altering long-term disease trajectory.
- Standardized outcomes will enable cross-trial comparison of disease-modifying interventions for the first time.
- The consensus followed rigorous COMET guidance, lending international credibility to the outcome set.
Methodology
A modified Delphi consensus process was conducted in two rounds (round one n=233; round two n=79) following COMET guidance. Candidate outcomes were derived from the literature and refined by an international multidisciplinary steering group including clinicians, researchers, and patients. Agreement was defined by pre-specified thresholds across voting rounds.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access; the complete list of 35 outcomes and domain definitions could not be reviewed. Multiple panel members disclosed significant financial relationships with pharmaceutical companies, which may have influenced outcome prioritization. Delphi methods reflect expert consensus rather than empirical evidence and may not capture novel biomarkers or patient subgroup heterogeneity.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: